C5 Perspectives of immunotherapy in the management of asthma and other allergic conditions
Publisher
Birkhäuser Basel
Reference82 articles.
1. Walsh GM. Emerging drugs for asthma. Expert Opin Emerg Drugs 2008; 13: 643–53 2. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A, Fick RB, Cockcroft DW. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835–40 3. Fahy J, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA. The effect of an anti-IgE mono clonal antibody on the early and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828–34 4. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Treatment of allergic asthma with monoclonal anti-IgE. N Engl J Med 1999; 341: 1966–73 5. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120: 688–95
|
|